Premium
MicroRNA‐326 and microRNA‐200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia
Author(s) -
Ghodousi Elaheh S.,
Rahgozar Soheila
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.26800
Subject(s) - microrna , drug resistance , fold change , multiple drug resistance , gene , reverse transcriptase , cancer research , multidrug resistance associated proteins , oncology , medicine , minimal residual disease , leukemia , polymerase chain reaction , biology , gene expression , immunology , transporter , genetics , atp binding cassette transporter
Multidrug resistance (MDR) is considered as the major obstacle for treating pediatric acute lymphoblastic leukemia (ALL). MicroRNAs (miRNAs) are small non coding RNAs which may potentially regulate response to chemotherapy. In this study, total RNA was isolated from bone marrow samples of 46 children with de novo ALL and 16 controls. Quantitative reverse transcriptase polymerase chain reaction was used to investigate the expression profile of the predicted miRNAs; miR‐326 and miR‐200c, and their predicted targets ABCA2, and ABCA3 transporters. The presence of minimal residual disease was studied using PCR‐SSCP (single‐strand conformation polymorphism) 1 year after treatment. The association between the miRNA expression and drug resistance was analyzed statistically. Results showed a significant down‐regulation of both miR‐326 and miR‐200c expressions in ALL patients compared with non‐cancer controls ( P = 0.0002, AUC = 0.813 and P = 0.035, AUC = 0.79, respectively). A considerable negative association between miR‐326 expression and MDR was identified which could raise the risk of chemoresistance by 4.8‐ fold. The expression profiles of miR‐326 and ABCA2 transporter were inversely correlated. Data revealed, a novel diagnostic role for miR‐326 and miR‐200c as potential biomarkers of pediatric ALL. Down‐regulation of miR‐326 was introduced, for the first time, as a prognostic factor for drug resistance in childhood ALL. To the best of our knowledge, this is the first time that ABCA2 transporter is proposed as a target gene for miR‐326, through which it can exert its impact on drug resistance. These data may provide novel approaches to new therapeutics and diagnostics.